Correlation Between Neuropace and Co Diagnostics

Can any of the company-specific risk be diversified away by investing in both Neuropace and Co Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Co Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and Co Diagnostics, you can compare the effects of market volatilities on Neuropace and Co Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Co Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Co Diagnostics.

Diversification Opportunities for Neuropace and Co Diagnostics

0.29

Correlation Coefficient

Neuropace  Co Diagnostics

Modest diversification

The 3 months correlation between Neuropace and CODX is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Co Diagnostics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Co Diagnostics and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Co Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Co Diagnostics has no effect on the direction of Neuropace i.e., Neuropace and Co Diagnostics go up and down completely randomly.

Pair Corralation between Neuropace and Co Diagnostics

Given the investment horizon of 90 days Neuropace is expected to generate 0.58 times more return on investment than Co Diagnostics. However, Neuropace is 1.73 times less risky than Co Diagnostics. It trades about 0.07 of its potential returns per unit of risk. Co Diagnostics is currently generating about -0.16 per unit of risk. If you would invest  1,087  in Neuropace on December 29, 2024 and sell it today you would earn a total of  151.00  from holding Neuropace or generate 13.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Neuropace  vs.  Co Diagnostics

Neuropace

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.

Co Diagnostics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Co Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Neuropace and Co Diagnostics

The main advantage of trading using opposite Neuropace and Co Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Co Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Co Diagnostics will offset losses from the drop in Co Diagnostics' long position.

The idea behind Neuropace and Co Diagnostics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.